[go: up one dir, main page]

WO2007141200A8 - Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases - Google Patents

Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases

Info

Publication number
WO2007141200A8
WO2007141200A8 PCT/EP2007/055376 EP2007055376W WO2007141200A8 WO 2007141200 A8 WO2007141200 A8 WO 2007141200A8 EP 2007055376 W EP2007055376 W EP 2007055376W WO 2007141200 A8 WO2007141200 A8 WO 2007141200A8
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
mch
aryl
heteroaryl substituted
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/055376
Other languages
French (fr)
Other versions
WO2007141200A1 (en
Inventor
Manuel Jesus Alcazar-Vaca
Jose Ignacio Andres-Gil
Frank Matthias Dautzenberg
Jacqueline Macritchie
Santamarina Julen Oyarzabal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of WO2007141200A1 publication Critical patent/WO2007141200A1/en
Publication of WO2007141200A8 publication Critical patent/WO2007141200A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention concerns N-aryl and N-heteroaryl substituted pyridinone derivatives having antagonistic melanin-concentrating hormone (MCH) activity, in particular MCH-1 activity according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful for the prevention and/or treatment of psychiatric disorders, including but not limited to anxiety, eating disorders, mood disorders, such as bipolar disorders and depression, psychoses, such as schizophrenia, and sleeping disorders; obesity; diabetes; sexual disorders and neurological disorders.
PCT/EP2007/055376 2006-06-02 2007-06-01 Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases Ceased WO2007141200A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06114917.5 2006-06-02
EP06114917 2006-06-02
EP06123263.3 2006-10-31
EP06123263 2006-10-31

Publications (2)

Publication Number Publication Date
WO2007141200A1 WO2007141200A1 (en) 2007-12-13
WO2007141200A8 true WO2007141200A8 (en) 2008-03-27

Family

ID=38266244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055376 Ceased WO2007141200A1 (en) 2006-06-02 2007-06-01 Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases

Country Status (5)

Country Link
AR (1) AR061163A1 (en)
PE (1) PE20080150A1 (en)
TW (1) TW200811146A (en)
UY (1) UY30378A1 (en)
WO (1) WO2007141200A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041090A1 (en) * 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
EP2240481A1 (en) * 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2437601A4 (en) * 2009-06-03 2012-10-31 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2010141539A1 (en) * 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011127643A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011130086A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
ES2873029T3 (en) 2010-12-06 2021-11-03 Aclaris Therapeutics Inc Substituted pyridinone-pyridinyl compounds
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2013149362A1 (en) * 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
MX2015000830A (en) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Nitrogenous heterocyclic derivatives and their application in drugs.
US9115089B2 (en) 2013-06-07 2015-08-25 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
CN116082225A (en) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 Preparation method of hydroxynisone
CN116023327A (en) * 2016-08-08 2023-04-28 北京康蒂尼药业股份有限公司 Preparation method of hydroxynisone
EP4076527A4 (en) * 2020-01-10 2024-05-15 Consynance Therapeutics, Inc. THERAPEUTIC ACTIVE INGREDIENT COMBINATIONS AND METHODS OF USE
MX2022011755A (en) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc PROCESS, COMPOSITIONS AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL218749B1 (en) * 2002-02-14 2015-01-30 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
JPWO2005085200A1 (en) * 2004-03-05 2008-01-17 萬有製薬株式会社 Pyridone derivative
JPWO2007024004A1 (en) * 2005-08-24 2009-03-05 萬有製薬株式会社 Phenylpyridone derivatives

Also Published As

Publication number Publication date
UY30378A1 (en) 2008-01-02
TW200811146A (en) 2008-03-01
AR061163A1 (en) 2008-08-06
WO2007141200A1 (en) 2007-12-13
PE20080150A1 (en) 2008-04-11

Similar Documents

Publication Publication Date Title
WO2007141200A8 (en) Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases
MX2009005908A (en) Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases.
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
WO2004082577A3 (en) 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
TW200500359A (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
MX2009005509A (en) 2-aminoquinolines as 5-ht(5a) receptor antagonists.
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
WO2008056266A3 (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
MX2010009643A (en) 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists.
WO2007057790A3 (en) Substituted bicyclic pyrimidone derivatives
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
WO2008077810A3 (en) Spiro-piperidine derivatives
MX2009002906A (en) Pyridine derivatives for the treatment of metabolic disorders related insulin resistance or haperglycemia.
TW200635906A (en) Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine
IL194740A0 (en) Substituted pyrazinone derivatives for use as a medicine
MX2010009403A (en) 2-aminoquinoline derivatives.
MX2009005504A (en) Spiro-piperidine derivatives as via receptor antagonists.
IL192240A0 (en) Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
TW200833696A (en) Spiro-piperidine derivatives
WO2010026110A3 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
JP2010527967A (en) Novel 2,3-diaminoquinazolinone derivatives and their use in medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07729777

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07729777

Country of ref document: EP

Kind code of ref document: A1